IL105879A - Pharmaceutical preparations containing paclitaxil - Google Patents

Pharmaceutical preparations containing paclitaxil

Info

Publication number
IL105879A
IL105879A IL10587993A IL10587993A IL105879A IL 105879 A IL105879 A IL 105879A IL 10587993 A IL10587993 A IL 10587993A IL 10587993 A IL10587993 A IL 10587993A IL 105879 A IL105879 A IL 105879A
Authority
IL
Israel
Prior art keywords
paclitaxel
infusion
cancer
patients
patient
Prior art date
Application number
IL10587993A
Other languages
English (en)
Hebrew (he)
Other versions
IL105879A0 (en
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25448992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL105879(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL105879A0 publication Critical patent/IL105879A0/xx
Publication of IL105879A publication Critical patent/IL105879A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IL10587993A 1992-08-03 1993-06-02 Pharmaceutical preparations containing paclitaxil IL105879A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92362892A 1992-08-03 1992-08-03

Publications (2)

Publication Number Publication Date
IL105879A0 IL105879A0 (en) 1993-10-20
IL105879A true IL105879A (en) 1998-08-16

Family

ID=25448992

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10587993A IL105879A (en) 1992-08-03 1993-06-02 Pharmaceutical preparations containing paclitaxil

Country Status (23)

Country Link
US (5) US5641803A (fr)
EP (3) EP0584001B1 (fr)
JP (1) JP2848760B2 (fr)
AT (1) ATE152910T1 (fr)
AU (3) AU641894B3 (fr)
BE (1) BE1006497A5 (fr)
CA (1) CA2086874E (fr)
CH (1) CH686868A5 (fr)
DE (2) DE69310634T2 (fr)
DK (2) DK65293A (fr)
ES (2) ES2105926B1 (fr)
FR (1) FR2694192B1 (fr)
GB (1) GB9311740D0 (fr)
GR (2) GR1001617B (fr)
IE (1) IE80620B1 (fr)
IL (1) IL105879A (fr)
IT (1) IT1276041B1 (fr)
MY (1) MY109862A (fr)
NL (1) NL9301086A (fr)
NZ (1) NZ245795A (fr)
PT (1) PT101289A (fr)
SE (1) SE513082C2 (fr)
ZA (1) ZA93686B (fr)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070117863A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5886026A (en) * 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
USRE38424E1 (en) * 1994-11-21 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Method for treating taxol side-effects with G-CSF
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
AU735900B2 (en) 1996-03-12 2001-07-19 Pg-Txl Company, L.P. Water soluble paclitaxel prodrugs
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US20030157187A1 (en) * 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
US20030087954A1 (en) * 1997-01-07 2003-05-08 Sonus Pharmaceuticals, Inc. Method of treating bladder carcinoma using a Taxane/Tocopherol formulation
US6727280B2 (en) * 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US20030105156A1 (en) * 1997-01-07 2003-06-05 Nagesh Palepu Method for administration of a taxane/tocopherol formulation to enhance taxane therapeutic utility
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
GB9705903D0 (en) 1997-03-21 1997-05-07 Elliott Gillian D VP22 Proteins and uses thereof
AU7486898A (en) 1997-05-13 1998-12-08 Stuart D Edwards Global medical treatment method and apparatus
NZ502500A (en) * 1997-06-27 2002-03-28 Vivorx Pharmaceuticals Inc Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
EP3266450A1 (fr) 1997-06-27 2018-01-10 Abraxis BioScience, LLC Nouvelles formes d'agents pharmacologiques, leurs procédés de préparation et procédés d'utilisation
HUP9701554D0 (en) 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
CA2298475A1 (fr) * 1997-10-31 1999-05-14 Walter Reed Army Institute Of Research Procede permettant d'inhiber les effets secondaires de compositions pharmaceutiques contenant des excipients amphiphiles ou des molecules vecteurs de medicaments
SK287775B6 (sk) * 1998-02-05 2011-09-05 Novartis Ag Farmaceutická formulácia obsahujúca epothilon, infúzny roztok a použitie farmaceutickej formulácie
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6121029A (en) 1998-06-18 2000-09-19 Novartis Ag Genes for the biosynthesis of epothilones
US7314637B1 (en) 1999-06-29 2008-01-01 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6461637B1 (en) * 2000-09-01 2002-10-08 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
US6472420B2 (en) * 1998-11-12 2002-10-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a paclitaxel derivative
US6235776B1 (en) * 1998-11-12 2001-05-22 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a paclitaxel derivative
EP1191948A2 (fr) * 1999-06-11 2002-04-03 Neorx Corporation Complexe a forte dose de radionucleides destine a la suppression de la moelle osseuse
TW422706B (en) 1999-07-01 2001-02-21 Wang Iz Rung An oil-in-water emulsion type of paclitaxel
US7094885B2 (en) * 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US20030054977A1 (en) * 1999-10-12 2003-03-20 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
US6828346B2 (en) * 1999-10-25 2004-12-07 Supergen, Inc. Methods for administration of paclitaxel
JP2001247459A (ja) 2000-03-03 2001-09-11 Oakland Uniservices Ltd 癌の組み合わせ療法
US20020077290A1 (en) * 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
US6569459B2 (en) 2000-04-10 2003-05-27 Teva Pharmaceutical Industries, Ltd. Method of administration of paclitaxel-plasma protein formulation
WO2002009700A1 (fr) 2000-07-28 2002-02-07 Cancer Research Technology Limited Traitement combine contre le cancer
CA2434302A1 (fr) 2001-01-08 2002-08-15 Neorx Corporation Composes, compositions et methodes therapeutiques et diagnostiques
ATE481097T1 (de) 2001-01-16 2010-10-15 Vascular Therapies Llc Implantierbare vorrichtung enthaltend resorbierbares matrixmaterial und antiproliferative wirkstoffe zur vorbeugung oder behandlung von versagen vaskulärer hämodialysezugänge und anderer vaskulärer transplantate
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US6548531B2 (en) 2001-02-09 2003-04-15 Hoffmann-La Roche Inc. Method for cancer therapy
US7666414B2 (en) * 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
US7514078B2 (en) * 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
WO2002098897A2 (fr) * 2001-06-01 2002-12-12 Cornell Research Foundation, Inc. Anticorps modifies diriges contre l'antigene prostatique specifique membranaire et utilisations associees
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
WO2003026581A2 (fr) * 2001-09-26 2003-04-03 Intermune, Inc. Compositions pharmaceutiques et methodes de traitement du cancer
US20030087837A1 (en) * 2001-10-15 2003-05-08 Jonas Jeffrey M. Compositions and methods for delivery of poorly water soluble drugs and methods of treatment
EP2316468A1 (fr) 2002-02-22 2011-05-04 Shire LLC Système de distribution et méthodes de protection et d'administration de dextroamphetamine
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
WO2003080027A1 (fr) * 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Compositions nanoparticulaires d'inhibiteurs d'angiogenese
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
AU2003227610A1 (en) * 2002-04-12 2003-10-27 Multimmune Gmbh Non-toxic amounts of protein-aggregating substances stimulate hsp70 expression and function as anti-tumor agents
AU2003273182B8 (en) * 2002-05-10 2009-05-07 Agennix Incorporated Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
CZ294371B6 (cs) * 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
US20040047835A1 (en) * 2002-09-06 2004-03-11 Cell Therapeutics, Inc. Combinatorial drug therapy using polymer drug conjugates
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
EA200501252A1 (ru) * 2003-02-03 2006-02-24 Неофарм, Инк. Липосомальная композиция, способ ее получения и лекарственное средство на ее основе (варианты)
WO2004080445A1 (fr) * 2003-03-12 2004-09-23 Molecular Engines Laboratories Sa Methodes et compositions pour le traitement du cancer
US7085886B2 (en) * 2003-05-28 2006-08-01 International Buisness Machines Corporation Autonomic power loss recovery for a multi-cluster storage sub-system
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
EP1610818A4 (fr) * 2004-03-03 2007-09-19 Millennium Pharm Inc Anticorps modifies diriges contre un antigene membranaire specifique de la prostate
US7989490B2 (en) * 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
SI3248600T1 (sl) 2005-02-18 2020-09-30 Abraxis Bioscience, Llc Kombinacije in načini dajanja terapevtskih sredstev in kombinacijska terapija
US20070003557A1 (en) * 2005-04-21 2007-01-04 Andres Forero Method for treating cancer using premedication
WO2006117220A2 (fr) 2005-05-04 2006-11-09 Medigene Ag Methode d'administration d'une preparation liposomale cationique
TWI376239B (en) * 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
EP2004175A4 (fr) * 2006-03-16 2010-12-15 Bionumerik Pharmaceuticals Inc Composés augmentant l'activité anticancéreuse, formulations les contenant et leurs méthodes d'utilisation
CA2646156C (fr) 2006-03-22 2016-05-24 Medigene Ag Traitement du cancer du sein avec = triple recepteur negatif =
WO2008004231A1 (fr) * 2006-07-07 2008-01-10 Tiltan Pharma Ltd. Traitement anticancéreux faisant appel à un h2-bloquant, à au moins un agent anti-inflammatoire et à un agent cytotoxique
WO2008105852A2 (fr) * 2006-10-26 2008-09-04 Creighton University Nanoparticules mucoadhésives pour traitement anticancéreux
JP5667886B2 (ja) 2008-03-14 2015-02-12 バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド 癌患者の生存時間を増大させるための組成物及び化合物の使用方法
JP5694782B2 (ja) 2008-03-14 2015-04-01 バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド 肺癌、腺癌及び他の病状のための治療方法及び組成物
MX2011009413A (es) 2009-03-11 2011-10-21 Ambit Biosciences Corp Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer.
PT2552415T (pt) 2010-03-29 2016-11-04 Abraxis Bioscience Llc Métodos de tratamento do cancro
ES2925531T3 (es) 2010-03-29 2022-10-18 Abraxis Bioscience Llc Procedimientos para mejorar la administración de fármacos y la eficacia de agentes terapéuticos
WO2011153010A1 (fr) 2010-06-04 2011-12-08 Abraxis Biosciences, Llc Procédés de traitement du cancer du pancréas
EP4218929A1 (fr) 2014-03-21 2023-08-02 AbbVie Inc. Anticorps anti-egfr et conjugués anticorps-médicament
JP2019521973A (ja) 2016-06-08 2019-08-08 アッヴィ・インコーポレイテッド 抗ｂｈ７−ｈ３抗体及び抗体薬物コンジュゲート
EP3468599A2 (fr) 2016-06-08 2019-04-17 AbbVie Inc. Anticorps anti-cd98 et conjugués anticorps-médicament
TW202304996A (zh) 2016-06-08 2023-02-01 美商艾伯維有限公司 抗-b7-h3抗體及抗體藥物結合物
CN109563167A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
AU2017277914A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-CD98 antibodies and antibody drug conjugates
US11154511B2 (en) 2016-09-29 2021-10-26 Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. Albumin pharmaceutical composition and preparation method therefor
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2629818B1 (fr) * 1988-04-06 1990-11-16 Centre Nat Rech Scient Procede de preparation du taxol
WO1992019765A1 (fr) * 1991-05-08 1992-11-12 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Procede de conception de traitements du cancer, procedes et compositions pharmaceutiques de traitements du cancer
FR2678833B1 (fr) * 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.

Also Published As

Publication number Publication date
FR2694192A1 (fr) 1994-02-04
ES2101261T3 (es) 1997-07-01
ITMI931714A0 (it) 1993-07-29
CH686868A5 (de) 1996-07-31
EP0783885A3 (fr) 1997-08-06
ES2105926A1 (es) 1997-10-16
US6414014B1 (en) 2002-07-02
JPH07233064A (ja) 1995-09-05
IL105879A0 (en) 1993-10-20
CA2086874E (fr) 2000-01-04
MY109862A (en) 1997-09-30
IE80620B1 (en) 1998-10-21
EP0584001B1 (fr) 1997-05-14
US5665761A (en) 1997-09-09
NL9301086A (nl) 1994-03-01
ZA93686B (en) 1993-09-06
DE4325927A1 (de) 1994-03-10
NZ245795A (en) 1999-05-28
EP0783886A2 (fr) 1997-07-16
SE9301951L (sv) 1994-02-07
DE69310634D1 (de) 1997-06-19
DE4325927B4 (de) 2004-04-15
AU704393B2 (en) 1999-04-22
EP0783885A2 (fr) 1997-07-16
GR1001617B (el) 1994-07-29
EP0584001A1 (fr) 1994-02-23
IE930433A1 (en) 1994-02-09
ITMI931714A1 (it) 1995-01-29
PT101289A (pt) 1994-04-29
GR3024415T3 (en) 1997-11-28
BE1006497A5 (fr) 1994-09-13
US5641803A (en) 1997-06-24
DK65293A (da) 1994-02-04
DK0584001T3 (da) 1997-08-25
JP2848760B2 (ja) 1999-01-20
SE513082C2 (sv) 2000-07-03
DE69310634T2 (de) 1998-01-02
GB9311740D0 (en) 1993-07-21
AU4207096A (en) 1996-04-26
ATE152910T1 (de) 1997-05-15
AU704393C (en) 2002-07-25
AU3216893A (en) 1994-02-10
EP0783886A3 (fr) 1997-07-23
CA2086874C (fr) 1998-09-01
AU641894B3 (en) 1993-09-30
US5621001A (en) 1997-04-15
FR2694192B1 (fr) 1995-01-27
IT1276041B1 (it) 1997-10-24
ES2105926B1 (es) 1998-07-01
CA2086874A1 (fr) 1994-02-04
US5670537A (en) 1997-09-23
SE9301951D0 (sv) 1993-06-08
DK65293D0 (da) 1993-06-04

Similar Documents

Publication Publication Date Title
US5641803A (en) Methods for administration of taxol
DE69233169T2 (de) Cisplatin und Topotecan enthaltende Zusammensetzung als antitumor.
AU2013402794B2 (en) Cancer treatment with combination of plinabulin and taxane
EP1169059B1 (fr) Utilisation de docetaxel combine a rhumab her2 pour le traitement de cancers
Tamura et al. Phase I study of paclitaxel by three‐hour infusion: hypotension just after infusion is one of the major dose‐limiting toxicities
US5496846A (en) Taxol treatment of breast cancer
JPH05505615A (ja) 医薬組成物
EP2254570B1 (fr) Combinaison comprenant du paclitaxel destinée au traitement du cancer des ovaires
JP2004501870A (ja) ガン患者における化学療法の副作用を軽減させる方法
WO2006124573A2 (fr) Traitement du cancer a l'aide de 2-desoxyglucose
GB2269319A (en) Compositions containing taxol
Dragnev et al. A dose escalation trial of biweekly docetaxel and gemcitabine with filgrastim or pegfilgrastim for the treatment of patients with advanced solid tumors
AU7179200A (en) Method of treatment of breast cancer
EP1707568B1 (fr) Composition pharmaceutique utilisée dans le traitement du cancer de l'ovaire
Riedel et al. Extravasation of paclitaxel (Taxol®)–clinical course
Boehnke The Evolving Role of Paclitaxel in Breast Cancer and the Ambulatory Care Setting

Legal Events

Date Code Title Description
NP Permission for amending the patent specification granted (section 66, patents law 1967)
KB Patent renewed
NP Permission for amending the patent specification granted (section 66, patents law 1967)
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees